Put a price on breakthroughs

TEXT START: Neolabs today are being asked to pull off two moonshots at once.

The Dissection

The text is designing a financing wrapper for frontier research. It moves the commercial burden from neolabs to incumbent frontier labs through pre-committed acquisition options, turning an independent startup into a research outpost whose exit is specified before the experiment begins.

That is a legitimate mechanism for allocating research risk during the transition period. It is not a solution to the structural problem. It makes the pipeline from breakthrough to concentrated AI ownership more efficient.

The Core Fallacy

The text mistakes a coordination and pricing problem for the terminal problem.

It assumes that if research risk is underwritten, the economic system remains viable. Under the Discontinuity Thesis, the decisive issue is not whether researchers can secure funding or whether investors can obtain an exit. The decisive issue is who owns and controls the AI capital after the breakthrough.

A pre-registered acquisition can solve Arrow’s information paradox. It cannot solve P1, P2, or P3. It does not preserve human productive participation, restore the wage-consumption circuit, or prevent frontier labs from absorbing the productive frontier. It merely ensures that more breakthroughs reach the Sovereigns who control compute, deployment, distribution, and infrastructure.

The proposed shift from 1-in-10,000 to 1-in-100 is also false precision. The research probability may improve by removing the product burden, but acquisition probability, enforceability, target durability, buyer solvency, replication risk, and bargaining power remain unmodeled.

Hidden Assumptions

• Frontier labs will remain willing and financially able to honor long-term acquisition commitments.
• A benchmark or capability target will reliably translate into durable economic value.
• Training recipes, once demonstrated, will not be rapidly replicated internally or elsewhere.
• A neolab can retain bargaining power after proving the result.
• Acquisition prices will remain meaningful as AI-generated capabilities compress margins and concentrate ownership.
• Venture investors will still have access to sufficiently liquid exit markets.
• Multiple frontier labs will continue competing openly rather than consolidating into a small Sovereign cartel.
• Legal, regulatory, compute, energy, and data constraints will not invalidate the offer.
• The team itself remains the scarce asset after the result is demonstrated.
• Converting researchers into acquisition targets is equivalent to preserving independent innovation.

The most important concealed premise is that a successful exit is the relevant measure of survival. It is relevant to the founders and investors. It is irrelevant to the majority whose economic role is eliminated by the resulting systems.

Social Function

This is a partial truth wrapped in transition management, prestige signaling, and elite self-exoneration.

The partial truth is useful: separating discovery from scaling can improve research allocation, and pre-registered prices can reduce uncertainty for founders and investors.

The anesthetic is the “win-win-win” framing. The winners are researchers, venture capital, and frontier-lab owners. The proposal says nothing about the people displaced when the acquired breakthrough makes cognitive labor cheaper, less necessary, and less negotiable. It treats the coming concentration of AI capital as an efficient market outcome rather than the mechanism of mass exclusion.

In DT terms, this is capital’s acquisition paperwork for the transition. Independent neolabs become feeder cells for Sovereigns. Researchers receive a better chance of becoming well-paid Servitors; they do not become owners of the productive system.

The Verdict

As a narrow R&D-financing mechanism, pre-registered acquisitions are coherent and potentially valuable. As a response to the Discontinuity Thesis, they fail completely.

The proposal removes one moonshot from the startup’s burden while accelerating the larger process: frontier labs capture the breakthroughs, absorb the teams, and consolidate control over AI capital. It does not avert obsolescence. It makes obsolescence more efficiently financed, more rapidly deployed, and easier for its beneficiaries to describe as innovation.